Fisher & Paykel Healthcare dodges worst of US tariff risk: Jarden

Fisher & Paykel Healthcare dodges worst of US tariff risk: Jarden
About 43% of Fisher & Paykel Healthcare’s revenue comes from the US. (Image: Supplied)
John Anthony
Jarden has raised its rating and target share price for Fisher & Paykel Healthcare by 10%, as Thursday’s US tariff announcements proved less damaging than expected.Following US President Donald Trump’s unveiling of “Liberation Day” tariffs, shares in Fisher & Paykel Healthcare (FPH), a company with significant export exposure to the US, traded as low as $32.60 in the wake of the announcement on Thursday. They were currently at $34.80.In a research note released late Thursday evening, Jarden analysts Adrian Allbon...

More Economy

Corporate tax relief still on Budget agenda
Economy

Corporate tax relief still on Budget agenda

Targeted relief rather than a company tax rate cut looks more likely.

Business confidence higher in 1Q
Economy

Business confidence higher in 1Q

Cost pressures are intensifying. 

End of the East Asian growth miracle?
Economy

Alan Bollard: End of the East Asian growth miracle?

The US is punishing Asia for failures at home.

Alan Bollard 5:00am
Pandora’s box has been opened
Economy

Cameron Bagrie: Pandora’s box has been opened

The writing has been on the wall for a while.